Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2016 07:00 ET | Source: Genocea Biosciences, Inc.

Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing

- Consistent efficacy across potential Phase 3 clinical trial endpoints - - Once-yearly or less frequent maintenance dosing expected - - Company to host conference call at 9 a.m. ET today - ...
February 29, 2016 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at the Cowen and Company 36th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced...
February 11, 2016 07:30 ET | Source: Genocea Biosciences, Inc.

Genocea Reports Fourth Quarter and Year-End 2015 Financial Results

- Multiple 2016 clinical milestones for GEN-003 for genital herpes anticipated -- Cancer vaccine strategy targeting generation of first clinical candidate in 2017 - CAMBRIDGE, Mass., Feb. 11, 2016...
February 04, 2016 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea to Host Fourth Quarter and Year End 2015 Financial Results Conference Call & Webcast on February 11, 2016

CAMBRIDGE, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced...
February 01, 2016 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at 2016 BIO CEO & Investor Conference

CAMBRIDGE, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today...
January 29, 2016 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003

- Top-line viral shedding data expected in mid-2016 -- Six month clinical efficacy data against potential Phase 3 endpoints expected in 2H 2016 -CAMBRIDGE, Mass., Jan. 29, 2016 (GLOBE NEWSWIRE) --...